Piper Sandler Maintains Overweight on Pulmonx, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jason Bednar maintains an Overweight rating on Pulmonx (NASDAQ:LUNG) and raises the price target from $15 to $17.
August 04, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on Pulmonx and raises the price target from $15 to $17, which could positively impact the stock's price.
The raised price target by Piper Sandler indicates a positive outlook for Pulmonx. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100